Search

Your search keyword '"A. Tourbah"' showing total 36 results
Start Over Author "A. Tourbah" Publisher ovid technologies (wolters kluwer health)
36 results on '"A. Tourbah"'

1. Prospective Characterization of Brain T2 Lesions Suggestive of Demyelination in Asymptomatic Patients diagnosed as Radiologically Isolated Syndrome (P14-4.011)

Author

Landes-Château, Cassandre, primary, Mondot, Lydiane, additional, Cohen, Mikael, additional, Callier, Céline, additional, Zephir, Helene, additional, Louapre, Celine, additional, Dubief, Francoise Durand, additional, Carra-Dalliere, Clarisse, additional, Thouvenot, Eric, additional, Le Page, Emmanuelle, additional, Ruet, Aurelie, additional, Berger, Eric, additional, Derache, Nathalie, additional, Clavelou, Pierre, additional, Moreau, Thibault, additional, Casez, Olivier, additional, Gout, Olivier, additional, De Seze, Jerome, additional, Ciron, Jonathan, additional, Wiertlewski, Sandrine, additional, Bourre, Bertrand, additional, Magy, Laurent, additional, Cabre, Philippe, additional, Pelletier, Jean, additional, Debouverie, Marc, additional, Stankoff, Bruno, additional, Creange, Alain, additional, Fagniez, Ombeline, additional, Pottier, Corinne, additional, Neau, Jean Philippe, additional, Camdessanche, Jean-Philippe, additional, Henry, Carole, additional, Beltran, Stephane, additional, Guennoc, Anne Marie, additional, Tourbah, Ayman, additional, Radji, Fatai, additional, Morel, Nathalie, additional, Boyer, Karine, additional, Al Khedr, Abdullatif, additional, Siva, Aksel, additional, Kantarci, Orhun, additional, Pelletier, Daniel, additional, Okuda, Darin, additional, and Lebrun-Frenay, Christine, additional

Published
2022
Full Text
View/download PDF

2. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults

Author

Cobo-Calvo, A., Ruiz, A., Maillart, E., Audoin, B., Zephir, H., Bourre, B., Ciron, J., Collongues, N., Brassat, D., Cotton, F., Papeix, C., Durand-Dubief, F., Laplaud, D., Deschamps, R., Cohen, M., Biotti, D., Ayrignac, X., Tilikete, C., Thouvenot, E., Brochet, B., Dulau, C., Moreau, T., Tourbah, A., Lebranchu, P., Michel, L., Lebrun-Frenay, C., Montcuquet, A., Mathey, G., Debouverie, M., Pelletier, J., Derache, N., Coustans, M., Rollot, F., De Seze, J., Vukusic, S., Marignier, R., Casey, D. R., Maze, D. M., Olaiz, D. J., Frangoulis, D. B., Debard, N., Vukusic, P. S., Zorila, D. C., Debouverie, P. M., Guillemin, P. F., Mathey, D. G., Ziegler, A., Edan, P. G., Le Page, D. E., Leray, D. E., Muraz, R., Brassat, P. D., Clanet, P. M., Peaureaux-Averseng, D. D., Dewas, C., Brochet, P. B., Ouallet, D. J., Ruet, D. A., Kounkou, K. K., De Seze, P. J., Collongues, D. N., Berthe, C., Vermersch, P. P., Hautecoeur, P. P., Deruelle, F., Papeix, D. C., Maillard, D. E., Lubetzki, P. C., Lebrun-Frenay, D. C., Cohen, D. M., Callier, C., Derache, D. N., Droulon, K., Labauge, P. P., Ayrignac, D. X., Carra-Dalliere, D. C., Pinna, F., Moreau, P. T., Fromont, D. A., Protin, A., Michel, D. L., Wiertlewski, D. S., Jousset, N., Berger, D. E., Chamard-Witkowski, D. L., Bereau, D. M., Cappe, C., Clavelou, P. P., Taithe, D. F., Moisset, D. X., Dumont, E., Pelletier, P. J., Audoin, P. B., Rico-Lamy, D. A., Di Lelio, B., Castelnovo, D. G., Stankoff, P. B., Giannesini, D. C., Heinzlef, D. O., Fagniez, D. O., Laage, D. C., Bourre, D. B., Lefaucheur, D. R., Maltete, D. D., Vimont, C., Al Khedr, D. A., Sehaki, S., Gout, D. O., Bensa, D. C., Cabre, P. P., Kasonde, D. I., Galli, P., Magy, P. L., Montcuquet, D. A., Nicol, M., Casez, D. O., Vaillant, D. M., Diop Kane, M., Camdessanche, P. J., Visneux, V., Guennnoc, D. A., Beltran, D. S., Meunier, G., Creange, P. A., Ayache, D. S., Abdellaoui, D. M., Pottier, D. C., Slesari, D. I., Sampaio, M., Deburghraeve?, D. V., Le Port, D., Ciron, D. J., Neau, P. J., Rabois, E., Labeyrie, D. C., Patry, D. I., Lescieux, E., Nifle, D. C., Servan, D. J., Pico, P. F., Chatagner, V., Camus-Jacqmin, D. M., Henry, D. C., Bottin, D. L., Castex, C., Diallo, S. S., Brisset, J. C., Cervenansky, F., Commovick, O., Defer, P. G., Durand-Dubief, D. F., Guttmann, P. C., Tourbah, P. A., Lifticariu, D. C., Constans, D. J., Tanguy, D. J., Dousset, P. V., Tourdias, D. T., Dardel, D. P., Oesterle, D. H., Gonin, D. S., Ricolfi, D. F., Grand, D. S., Krainik, D. A., Boncoeur-Martel, D. M., Ameli, D. R., Bonhomme, D. G., Cotton, P. F., Roch, D. J., Sappey-Marinier, D. D., Brunel, H., Coze, S., Girard, Nicolas, Lehmann, P., Ranjeva, P. J., Menjot De Champfleur, Nicolas, Anxionnat, P. R., Desal, D. H., Mondot, D. L., Savatovsky, D. J., Galanaud, P. D., Pyatigorskaya, D. N., Guillevin, D. R., Pierot, D. L., Barillot, D. C., Ferre, D. J., Bannier, E., Gerardin, D. E., Boutet, D. C., Kremer, D. S., Armspach, P. J., Berry, P. I., Bonneville, P. F., Dufay, N., Zephir, D. H., Gele, P., Marignier, D. R., Fiard, G., Lehmann, S., Lommazi, S., Laplaud, P. D., Gallot, G., Thouvenot, P. E., Fontaine, P. B., Rebeix, I., Desille-Dugast, M., CHU Pitié-Salpêtrière [APHP], Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital de Hautepierre [Strasbourg], Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], RMN et optique : De la mesure au biomarqueur, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Neuroradiologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Département de Neurologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-IFR70-CHU Pitié-Salpêtrière [APHP], Department of Neurology, CHU Lyon, Centre Hospitalier Universitaire de Nice (CHU Nice), Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Universitaire de Reims (CHU Reims), Observatoire astronomique de Strasbourg (ObAS), Université de Strasbourg (UNISTRA)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis - Faculté de Médecine (UNS UFR Médecine), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Neurologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Hospices Civils de Lyon (HCL), CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre hospitalier universitaire de Nantes (CHU Nantes), The Functional Electrical Neuroimaging Laboratory, Université de Lausanne (UNIL), Department of Economics, École Polytechnique, Palaiseau Cedex, 91128, France, affiliation inconnue, Alimentation et sciences sociales (ALISS), Institut National de la Recherche Agronomique (INRA), CHU Marseille, Infections Virales et Pathologie Comparée - UMR 754 (IVPC), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, ISL, Laboratoire Charles Coulomb (L2C), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Instituto de Tecnologia Ceramica, Universitat Jaume I, CHU Grenoble, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Service de Neurologie [Rennes] = Neurology [Rennes], CHU Pontchaillou [Rennes], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital de Hautepierre [Strasbourg]-Nouvel Hôpital Civil de Strasbourg, Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Neurologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lausanne = University of Lausanne (UNIL), Institut National de la Recherche Agronomique (INRA)-École Pratique des Hautes Études (EPHE), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
0301 basic medicine, medicine.medical_specialty, Visual acuity, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, business.industry, Hazard ratio, Encephalopathy, Myelitis, Retrospective cohort study, Lower risk, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Internal medicine, medicine, Optic neuritis, Neurology (clinical), medicine.symptom, 10. No inequality, business, ComputingMilieux_MISCELLANEOUS, 030217 neurology & neurosurgery, Survival analysis
Abstract

ObjectiveTo describe clinical and radiologic features associated with myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) in a large French nationwide adult cohort, to assess baseline prognostic features of MOG-Ab-associated diseases after a first acute demyelinating syndrome, and to evaluate the clinical value of MOG-Ab longitudinal analysis.MethodsClinical data were obtained from 197 MOG-Ab-positive patients ≥18 years of age. Complete imaging data were available in 108, and 54 serum samples were eligible for longitudinal evaluation. For survival analysis comparison, 169 aquaporin-4 antibody (AQP4-Ab)-positive patients from the NOMADMUS database were included.ResultsMedian age at onset was 36.46 (range 18.0–76.8) years, and patients were predominantly white (92.9%) with male:female ratio, 1.1. Clinical phenotype at onset included optic neuritis or myelitis in 90.86%, isolated brainstem or encephalopathy syndromes in 6.6%, and a combination of syndromes in 2.5%. Distinctive brain MRI findings in MOG-Ab-positive patients were thalamic and pontine lesions. Cortical and leptomeningeal lesions were found in 16.3% and 6.1%, respectively. The probability of reaching a first relapse after 2 and 5 years was 44.8% and 61.8%, respectively. MOG-Ab-positive patients were at lower risk at presentation of further clinical relapse (hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.26–0.79) compared to AQP4-Ab-positive individuals. MOG-Ab-positive individuals had a lower risk of reaching Disability Status Scale score of 3.0 (HR 0.46, 95% CI 0.22–0.94) and visual acuity of 20/100 (HR 0.23, 95% CI 0.07–0.72). Finally, MOG-Ab titers were higher at relapse than in remission (p = 0.009).ConclusionIn adults, MOG-Ab-associated disease extends beyond clinical and radiologic abnormalities in the optic nerve and spinal cord. Despite the relapsing course, the overall visual and motor outcome is better compared with AQP4-Ab-positive patients.

Published
2018
Full Text
View/download PDF

3. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab

Author

Fissolo, Nicolás, primary, Pignolet, Beatrice, additional, Rio, Jordi, additional, Vermersch, Patrick, additional, Ruet, Aurélie, additional, deSèze, Jerome, additional, Labauge, Pierre, additional, Vukusic, Sandra, additional, Papeix, Caroline, additional, Martinez-Almoyna, Laurent, additional, Tourbah, Ayman, additional, Clavelou, Pierre, additional, Moreau, Thibault, additional, Pelletier, Jean, additional, Lebrun-Frenay, Christine, additional, Bourre, Bertrand, additional, Defer, Gilles, additional, Montalban, Xavier, additional, Brassat, David, additional, and Comabella, Manuel, additional

Published
2021
Full Text
View/download PDF

4. Clinical Evaluation of a Software Medical Device for the Self-Assessment of Patients Living with Multiple Sclerosis: Results of the MSCopilot Study (P3.2-012)

Author

Maillart, Elisabeth, primary, Labauge, Pierre, additional, Cohen, Mikael, additional, Maarouf, Adil, additional, Vukusic, Sandra, additional, Donzé, Cécile, additional, Gallien, Philippe, additional, De Sèze, Jérôme, additional, Bourre, Bertrand, additional, Moreau, Thibault, additional, Bieuvelet, Séverine, additional, Vallée, Morgane, additional, Bertillot, Fabien, additional, Argoud, Anne-Laure, additional, Zinai, Saad, additional, and Tourbah, Ayman, additional

Published
2019
Full Text
View/download PDF

8. MD1003 in Progressive Multiple Sclerosis: 24-Month Brain Volume Changes of the MS-SPI Trial (P6.365)

Author

Arnold, Douglas, primary, Ranjeva, Jean-Philippe, additional, Pelletier, Jean, additional, Barillot, Christian, additional, Jean, Betty, additional, Galanaud, Damien, additional, Pierot, Laurent, additional, Edan, Gilles, additional, Clavelou, Pierre, additional, SEDEL, Frederic, additional, Tourbah, Ayman, additional, and Berry, Isabelle, additional

Published
2018
Full Text
View/download PDF

9. Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients (S13.003)

Author

Whittam, Daniel, primary, Cobo-Calvo, Alvaro, additional, Lopez-Chiriboga, Alfonso Sebastian, additional, Pardo, Santiago, additional, Dodd, James, additional, Brandt, Alexander, additional, Berek, Klaus, additional, Berger, Thomas, additional, Gombolay, Grace, additional, Oliveira, Luana Micheli, additional, Callegaro, Dagoberto, additional, Kaneko, Kimihiko, additional, Misu, Tatsuro, additional, Brochet, Bruno, additional, Audoin, Bertrand, additional, Mathey, Guillaume, additional, Laplaud, David, additional, Thouvenot, Eric, additional, Cohen, Mikael, additional, Tourbah, Ayman, additional, Maillart, Elisabeth, additional, Ciron, Jonathan, additional, Deschamps, Romain, additional, Biotti, Damien, additional, Matiello, Marcelo, additional, Palace, Jacqueline, additional, Lim, Ming, additional, Fujihara, Kazuo, additional, Nakashima, Ichiro, additional, Bennett, Jeffrey, additional, Pandit, Lekha, additional, Chitnis, Tanuja, additional, Weinshenker, Brian, additional, Wildemann, Brigitte, additional, Sato, Douglas Kazutoshi, additional, Kim, Su-Hyun, additional, Kim, Ho Jin, additional, Reindl, Markus, additional, Levy, Michael, additional, Jarius, Sven, additional, Tenembaum, Silvia, additional, Paul, Friedemann, additional, Pittock, Sean, additional, Marignier, Romain, additional, and Jacob, Anu, additional

Published
2018
Full Text
View/download PDF

10. Efficacy and safety of alemtuzumab in 113 patients with active relapsing-remitting MS: one-year follow-up in France (P5.347)

Author

Ayrignac, Xavier, primary, Collongues, Nicolas, additional, De Seze, Jerome, additional, Vermersch, Patrick, additional, Biotti, Damien, additional, BRASSAT, DAVID, additional, Vukusic, Sandra, additional, Durand-Dubief, Françoise, additional, Edan, Gilles, additional, Lepage, Emmanuelle, additional, Deburghgraeve, Veronique, additional, Maillart, Elisabeth, additional, Papeix, Caroline, additional, Alla, Philippe, additional, Berger, Eric, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, Pittion, Sophie, additional, Debouverie, Marc, additional, Theaudin, Marie, additional, Derache, Nathalie, additional, Defer, Gilles, additional, Gout, Olivier, additional, Deschamps, Romain, additional, Tourbah, Ayman, additional, Zagnoli, Fabien, additional, Ruet, Aurelie, additional, Ouallet, Jean, additional, Brochet, Bruno, additional, Manchon, Eric, additional, Moreau, Thibault, additional, Fromont, Agnes, additional, Clavelou, Pierre, additional, Guennoc, Anne Marie, additional, Camdessanche, Jean-Phillippe, additional, Carpentier, Antoine, additional, Coman, Irene Antoanela, additional, Audoin, Bertrand, additional, Pelletier, Jean, additional, Magy, Laurent, additional, Ciron, Jonathan, additional, Wiertlevski, Sandrine, additional, Laplaud, David, additional, De Broucker, Thomas, additional, Frenay, Christine Lebrun, additional, Cohen, Mikael, additional, and Labauge, Pierre, additional

Published
2017
Full Text
View/download PDF

11. Natalizumab-PML survivors with subsequent MS treatment

Author

Maillart, Elisabeth, primary, Vidal, Jean-Sebastien, additional, Brassat, David, additional, Stankoff, Bruno, additional, Fromont, Agnès, additional, de Sèze, Jérôme, additional, Taithe, Frédéric, additional, Clavelou, Pierre, additional, Bourre, Bertrand, additional, Delvaux, Valérie, additional, Rico, Audrey, additional, Labauge, Pierre, additional, Tourbah, Ayman, additional, Lebrun, Christine, additional, Pelletier, Jean, additional, Moreau, Thibault, additional, Louapre, Céline, additional, Lubetzki, Catherine, additional, and Papeix, Caroline, additional

Published
2017
Full Text
View/download PDF

12. Focal Neurological Signs in Hepatic Encephalopathy in Cirrhotic Patients: An Underestimated Entity?

Author

Dominique Valla, Jean-François Cadranel, Bernard Pidoux, Sarkis El Koury, B Bernard, Eric Lebiez, Ayman Tourbah, Pierre Opolon, and Vincent Di Martino

Subjects
Liver Cirrhosis, Male, Neurological signs, Pathology, medicine.medical_specialty, Time Factors, Cirrhosis, Encephalopathy, Hemiplegia, Gastroenterology, Central nervous system disease, Sex Factors, Internal medicine, medicine, Humans, Prospective Studies, Prospective cohort study, Hepatic encephalopathy, Neurologic Examination, Hepatology, business.industry, Follow up studies, Middle Aged, Prognosis, medicine.disease, Case-Control Studies, Hepatic Encephalopathy, Female, Complication, business, Follow-Up Studies
Abstract

Focal neurological signs have been poorly documented in the course of hepatic encephalopathy in cirrhotic patients because they are not mentioned in any textbooks of liver diseases. Having the opportunity to observe such cases, we underwent a prospective study to determine incidence, characteristics, associated factors, prognostic significance, and outcome of this rare form of hepatic encephalopathy.Over a 12-month period, all cirrhotic patients hospitalized in the intensive care unit of our department for hepatic encephalopathy were prospectively studied. Patients with clinical and electroencephalogram evidences of hepatic encephalopathy were examined by a senior physician and, in cases of focal neurological signs, underwent examination by a neurologist, CT scan, lumbar punction, and cerebral magnetic resonance imaging and echo Doppler examination of neck and head vessels. Clinical and biological parameters were compared in patients during episodes with and without focal neurological signs, and outcome was noted.Thirty-four cirrhotic patients were hospitalized for 48 episodes of hepatic encephalopathy; two of these patients with cerebral hematoma were excluded. Twenty-four patients exhibited 38 hepatic encephalopathy episodes without focal neurological signs (82.6%), and eight patients exhibited eight hepatic encephalopathy episodes with focal neurological signs (17.4%) that were hemiplegia and hemiparesia in six patients (75%). In all patients, cerebral CT scan and cerebrospinal fluid examination disclosed no abnormalities, as neither did cerebral magnetic resonance imaging (n = 5) and echo Doppler examination of neck and head vessels (n = 5). Except for female sex, which was more often encountered in patients with focal neurological signs (p0.05), there were no differences between episodes with and without focal neurological signs for any of the parameters studied. In surviving patients who recovered from hepatic encephalopathy (7/8), focal neurological signs disappeared without recurrences after follow up of 6 months (3-12).Hepatic encephalopathy with focal neurological signs when carefully searched is not uncommon. It could be more frequent in cirrhotic females, is reversible, and has no prognostic significance.

Published
2001
Full Text
View/download PDF

13. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

Author

Pignolet, Béatrice, primary, Schwab, Nicholas, additional, Schneider-Hohendorf, Tilman, additional, Bucciarelli, Florence, additional, Biotti, Damien, additional, Averseng-Peaureaux, Delphine, additional, Outteryck, Olivier, additional, Ongagna, Jean-Claude, additional, de Sèze, Jérôme, additional, Brochet, Bruno, additional, Ouallet, Jean-Christophe, additional, Debouverie, Marc, additional, Pittion, Sophie, additional, Defer, Gilles, additional, Derache, Nathalie, additional, Hautecoeur, Patrick, additional, Tourbah, Ayman, additional, Labauge, Pierre, additional, Castelnovo, Giovanni, additional, Clavelou, Pierre, additional, Berger, Eric, additional, Pelletier, Jean, additional, Rico, Audrey, additional, Zéphir, Hélène, additional, Laplaud, David, additional, Wiertlewski, Sandrine, additional, Camu, William, additional, Thouvenot, Eric, additional, Casez, Olivier, additional, Moreau, Thibault, additional, Fromont, Agnès, additional, Vukusic, Sandra, additional, Papeix, Caroline, additional, Vermersch, Patrick, additional, Comabella, Manuel, additional, Lebrun-Frenay, Christine, additional, Wiendl, Heinz, additional, and Brassat, David, additional

Published
2016
Full Text
View/download PDF

14. Effect of MD1003 (High Doses of Biotin) in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis (MS-ON): Results of a Pivotal Randomized Double Masked Placebo Controlled Study (S49.005)

Author

Tourbah, Ayman, primary, Arndt, Carl, additional, Vighetto, Alain, additional, Deburghgraeve, Véronique, additional, Pelletier, Jean, additional, Papeix, Caroline, additional, Lebrun-Frenay, Christine, additional, Labauge, Pierre, additional, Clanet, Michel, additional, Toosy, Ahmed, additional, Laplaud, David, additional, Vermersch, Patrick, additional, Moreau, Thibault, additional, Debouverie, Marc, additional, Clavelou, Pierre, additional, Heinzlef, Olivier, additional, De Seze, Jerome, additional, Defer, Gilles, additional, Sedel, Frederic, additional, and Gout, Olivier, additional

Published
2016
Full Text
View/download PDF

15. 24-Month-Treatment with-MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of the MS-SPI Trial Extension Phase (S49.004)

Author

Tourbah, Ayman, primary, Lebrun-Frenay, Christine, additional, Edan, Gilles, additional, Clanet, Michel, additional, Papeix, Caroline, additional, Vukusic, Sandra, additional, De Seze, Jerome, additional, Debouverie, Marc, additional, Gout, Olivier, additional, Clavelou, Pierre, additional, Defer, Gilles, additional, Laplaud, David, additional, Moreau, Thibault, additional, Labauge, Pierre, additional, Brochet, Bruno, additional, Sedel, Frederic, additional, and Pelletier, Jean, additional

Published
2016
Full Text
View/download PDF

16. Comparative efficacy of fingolimod vs natalizumab

Author

Barbin, Laetitia, primary, Rousseau, Chloe, additional, Jousset, Natacha, additional, Casey, Romain, additional, Debouverie, Marc, additional, Vukusic, Sandra, additional, De Sèze, Jerome, additional, Brassat, David, additional, Wiertlewski, Sandrine, additional, Brochet, Bruno, additional, Pelletier, Jean, additional, Vermersch, Patrick, additional, Edan, Gilles, additional, Lebrun-Frenay, Christine, additional, Clavelou, Pierre, additional, Thouvenot, Eric, additional, Camdessanché, Jean-Philippe, additional, Tourbah, Ayman, additional, Stankoff, Bruno, additional, Al Khedr, Abdullatif, additional, Cabre, Philippe, additional, Papeix, Caroline, additional, Berger, Eric, additional, Heinzlef, Olivier, additional, Debroucker, Thomas, additional, Moreau, Thibault, additional, Gout, Olivier, additional, Bourre, Bertrand, additional, Créange, Alain, additional, Labauge, Pierre, additional, Magy, Laurent, additional, Defer, Gilles, additional, Foucher, Yohann, additional, and Laplaud, David A., additional

Published
2016
Full Text
View/download PDF

17. Clinical and molecular features of spinocerebellar ataxia type 6

Author

Géraldine Cancel, J.-M. Warter, Gilles David, Olivier Didierjean, Giovanni Stevanin, Yves Agid, Alexis Brice, Alexandra Durr, Ayman Tourbah, and S. Rivaud

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, Pathology, medicine.medical_specialty, Cerebellar ataxia, Biology, Spinocerebellar Degenerations, medicine.disease, Central nervous system disease, Olivopontocerebellar atrophy, medicine, Spinocerebellar ataxia type 6, Cerebellar atrophy, Neurology (clinical), Age of onset, medicine.symptom, Allele frequency
Abstract

The mutation involved in spinocerebellar ataxia type 6 (SCA6) is a small CAG expansion in the alpha-1A subunit of the voltage-dependent calcium channel gene. We looked for this mutation in 91 families with autosomal-dominant cerebellar ataxias and found that SCA6 is a minor locus in our series (2%) and is rare in France (1%). Furthermore, we did not detect the SCA6 mutation on 146 sporadic cases with isolated cerebellar ataxia or olivopontocerebellar atrophy. The normal and expanded alleles ranged from 4 to 15 and 22 to 28 CAG repeats, respectively, and age at onset was correlated to CAG repeat length (r = -0.87). In contrast with other SCA, the expanded allele was stable during transmission. Clinically, SCA6 patients (n = 12) presented with moderate to severe cerebellar ataxia with a lower frequency of associated signs compared with other SCA and a mean age at onset of 45± 14 years (range, 24 to 67). MRI showed extensive cerebellar atrophy but not of the brainstem or cerebral cortex.

Published
1997
Full Text
View/download PDF

19. Effect of MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of a Pivotal Phase III Randomized Double Blind Placebo Controlled Study (PL2.002)

Author

Tourbah, Ayman, primary, Lebrun Frenay, Christine, additional, Edan, Gilles, additional, Clanet, Michel, additional, Papeix, Caroline, additional, Vukusic, Sandra, additional, De Seze, Jerome, additional, Debouverie, Marc, additional, Gout, Olivier, additional, Clavelou, Pierre, additional, Defer, Gilles, additional, Laplaud, David, additional, Moreau, Thibault, additional, Labauge, Pierre, additional, Brochet, Bruno, additional, Sedel, Frederic, additional, and Pelletier, Jean, additional

Published
2015
Full Text
View/download PDF

20. Results of a Phase 1b study to confirm safety and tolerability of olesoxime in multiple sclerosis patients (P7.282)

Author

Pelletier, Jean, primary, Ranjeva, Jean-Philippe, additional, Tourbah, Ayman, additional, Edan, Gilles, additional, Barillot, Christian, additional, Le La Mer, Sophie, additional, Audoin, Bertrand, additional, Rico Lamy, Audrey, additional, Crespy, Lydie, additional, Ridley, Ben, additional, Zaaraoui, Wafaa, additional, Confort-Gouny, Sylviane, additional, Guye, Maxime, additional, Maarouf, Adil, additional, Caucheteux, Nathalie, additional, Chaunu, Marie-Pierre, additional, Portefaix, Christophe, additional, Pierot, Laurent, additional, Commowick, Olivier, additional, Kerbrat, Anne, additional, Catanese, Laurence, additional, Cuvier, Valerie, additional, Veys, Julien, additional, Pruss, Rebecca, additional, and Hauke, Wilfried, additional

Published
2015
Full Text
View/download PDF

24. ENIGM: A French Observational Study about Switching from Natalizumab to Fingolimod in Multiple Sclerosis (S41.002)

Author

Cohen, Mikael, primary, Maillart, Elisabeth, additional, Papeix, Caroline, additional, Vukusic, Sandra, additional, Brassat, David, additional, De Seze, Jerome, additional, Tourbah, Ayman, additional, Wiertlewski, Sandrine, additional, Laplaud, David, additional, Courtois, Sylvie, additional, Derouiche, Faycal, additional, Chambaud, Loic, additional, Boulay, Clotilde, additional, Brochet, Bruno, additional, Debouverie, Marc, additional, Casez, Olivier, additional, Heinzlef, Olivier, additional, Ouallet, Jean, additional, Stankoff, Bruno, additional, Castelnovo, Giovanni, additional, Le Page, Emmanuelle, additional, Defer, Gilles, additional, Derache, Nathalie, additional, Anne, Olivier, additional, Berger, Eric, additional, Rumbach, Lucien, additional, Camdessanche, Jean-Phillippe, additional, Kopf, Audrey, additional, Fleury, Marie, additional, Malikova, Irina, additional, Pelletier, Jean, additional, Al Khedr, Abdullatif, additional, Zaenker, Christian, additional, Edan, Gilles, additional, Moreau, Thibault, additional, Fromont, Agnes, additional, Rico, Audrey, additional, Blanc, Frederic, additional, Collongues, Nicolas, additional, Barth, Pascal, additional, Louiset, Pierre, additional, Pittion, Sophie, additional, Clavelou, Pierre, additional, Taithe, Frederic, additional, Vermersch, Patrick, additional, Zephir, Helene, additional, Creange, Alain, additional, Gout, Olivier, additional, Guennoc, Anne Marie, additional, Coustans, Marc, additional, Taurin, Gregory, additional, Lallement, Francois, additional, Rouhart, Francois, additional, Camu, William, additional, Thouvenot, Eric, additional, Labauge, Pierre, additional, Dive, Dominique, additional, Seeldrayers, Pierrette, additional, and Lebrun Frenay, Christine, additional

Published
2013
Full Text
View/download PDF

26. Correlation between Brain MRI and Health Related Quality of Life in Early Treated MS Patients and Clinically Isolated Syndrome (P03.051)

Author

Bruno Brochet, Mikael Cohen, Patrick Vermersch, Christine Lebrun Frenay, Emmanuelle Le Page, Ayman Tourbah, Pierre Clavelou, and Thibault Moreau

Subjects
Health related quality of life, medicine.medical_specialty, Clinically isolated syndrome, business.industry, McDonald criteria, Mean age, Disease course, Lesion load, Internal medicine, Brain mri, Physical therapy, Medicine, Neurology (clinical), business, Prospective cohort study
Abstract

Objective: To compare brain MRI and health related quality of life (HRQOL) at the initiation of disease modifying therapy (DMD) in patients with clinically isolated syndrome (CIS) and clinically definite multiple sclerosis (CDMS). Background Few studies assessed correlation between MRI and HRQOL. In a previous study, we reported negative correlations between HRQOL, lesion load (LL) and brain parenchymal fraction (BPF) in early treated CDMS patients. Design/Methods: Our prospective study included patients with either CIS fulfilling 2005 McDonald criteria or CDMS. Patients started their first DMD at the inclusion. Annual assessment included clinical data, EDSS score, French version of MSQol-54 questionnaire, and 1.5T conventional brain MRI (T1 with and without gadolinium injection, T2 spin echo, proton density and FLAIR sequences). Images were analysed using the SepINRIA software to obtain T2-LL and BPF. Results: 60 patients were included. Mean age was 32 years (16-49) and F/M sex ratio was 2.2. Mean baseline EDSS was 1 (0-5). CIS patients differed from CDMS group by a lower EDSS score (mean 0.8 vs. 1.7, p=0.003), a lower T2-LL (2.8 vs. 6.5 cc3, p=0.002). BPF was not significantly different between the two groups (91.7% vs 90.5%, p=0.2). At the beginning of DMD, HRQOL was significantly better in CIS group considering total, physical and mental components. In CDMS group, T2-LL was significantly correlated to "role limitations-physical" (Pearson9s r coefficient: -0.45, p=0.04) and "role limitations-emotional" (r=-0.44, p=0.05) scores, whereas in CIS group, it was only correlated to "role limitations-emotional" (r=-0.427, p=0.05), independently of EDSS. Conclusions: Results suggest that alteration of physical dimensions of HRQOL is associated with accumulation of T2 lesions during disease course. Therefore, earlier DMD initiation could prevent degradation of HRQOL during follow-up. Longitudinal study is on going to assess impact of early treatment on HRQOL and potential correlations with brain MRI parameters. Supported by: Grants from Merck Serono and Bayer Schering Pharma. Disclosure: Dr. Cohen has received personal compensation for activities with Schering-Plough Corporation, Biogen Idec, Serono, Inc., Teva Neuroscience, and Sanofi-Aventis Pharmaceuticals, and Novartis. Dr. Brochet has received personal compensation for activities with Bayer HealthCare, Novartis, Merck Serono, and Biogen Idec. Dr. Brochet has received personal compensation in an editorial capacity for LEN. Dr. Brochet has received research support from Merck Serono, Biogen Idec, and Bayer HealthCare. Dr. Clavelou has received personal compensation for activities with Schering-Plough Corporation, Biogen Idec, Serono, Inc., and Sanofi-Aventis Pharmaceuticals, Inc. as a speaker. Dr. Le Page has nothing to disclose. Dr. Vermersch has received personal compensation for activites with Merck Serono, Bayer Schering, Teva-Aventis, Biogen Idec, Allmirall, and Novartis as a consultant and/or speaker. Dr. Tourbah has received personal compensation for activities with Schering AG, Biogen Idec, Serono, Inc. and Sanofi-Aventis Pharmaceuticals, Inc. as a speaker. Dr. Moreau has received research support from Biogen Idec, Sanofi Aventis and Teva Pharma, Bayer Schering, Merck Serono and Novartis. Dr. Lebrun has received personal compensation for activities with Schering, Biogen Idec, Serono and Sanofi as a speaker.Dr. Lebrun has received personal compensation in an editorial capacity for Elsevier.

Published
2012
Full Text
View/download PDF

27. Paroxysmal dystonia (tonic spasm) in multiple sclerosis

Author

Yves Agid, Paul Alizé, Ayman Tourbah, and Emmanuelle Waubant

Subjects
Adult, Multiple Sclerosis, Dysesthesia, Internal capsule, medicine.diagnostic_test, business.industry, Lenticular nucleus, Brain, Magnetic resonance imaging, Magnetic Resonance Imaging, body regions, Lesion, Dystonia, medicine.anatomical_structure, Paroxysmal dystonia, Forearm, Anesthesia, Hyperventilation, Humans, Medicine, Female, Neurology (clinical), medicine.symptom, business
Abstract

A 34-year-old woman presented with a history of paresthesia up to T6. MRI displayed two T2-bright signals: one occipital and one intraspinal at the T4 level. Oligoclonal bands were present in the spinal fluid. The patient was considered at risk to develop MS. Five weeks after dysesthesia had resolved, a right-sided segmental dystonia developed over 24 hours consisting of flexed posture of the hand, extension and abduction of fingers, with adduction of the thumb, forearm flexion on the arm, and extension of the shoulder. The contractions sometimes also involved the right side of the face and neck as well as the proximal lower limb (slight hip flexion). Each episode lasted 15 to 30 seconds. Initially, these contractions occurred rarely, then up to more than 100 times a day within a few days. Hyperventilation precipitated the attacks during which the patient remained fully conscious without speech difficulties. These involuntary contractions prevented daily activities. The only other neurologic finding was a simultaneous mild weakness of right finger extension and abduction. A brain MRI performed 3 days after onset of the paroxysmal dystonia and 4 weeks after the first brain MRI showed a large T2-bright lesion that was not visible on the initial MRI scan. This left-sided T2-bright signal involved the lateral part of the thalamus, the posterior limb of the internal capsule, and the internal part of the lenticular nucleus (figure, A). Postgadolinium, T1-weighted sequences showed enhancement restricted to the posterior limb of the internal capsule and the internal part of the lenticular nucleus (figure, B), reflecting the active breakdown of the blood–brain barrier. One gram methylprednisolone every day for 3 days did not improve the severity and frequency of the dystonic movements, although acetazolamide 250 mg BID stopped it within a few hours. Acetazolamide treatment was discontinued after 1 month. Symptoms did not recur.

Published
2001
Full Text
View/download PDF

31. Clinical and spectroscopic improvement in HIV-associated cognitive impairment

Author

Stankoff, B., primary, Tourbah, A., additional, Suarez, S., additional, Turell, E., additional, Stievenart, J.L., additional, Payan, C., additional, Coutellier, A., additional, Herson, S., additional, Baril, L., additional, Bricaire, F., additional, Calvez, V., additional, Cabanis, E.A., additional, Lacomblez, L., additional, and Lubetzki, C., additional

Published
2001
Full Text
View/download PDF

34. Clinical and spectroscopic improvement in HIV-associated cognitive impairment

Author

Christine Payan, S. Herson, S. Suarez, François Bricaire, Catherine Lubetzki, Bruno Stankoff, Laurence Baril, Ayman Tourbah, E. Turell, A. Coutellier, Lucette Lacomblez, E.A. Cabanis, Vincent Calvez, and J.L. Stievenart

Subjects
Adult, Male, medicine.medical_specialty, AIDS Dementia Complex, Magnetic Resonance Spectroscopy, medicine.medical_treatment, Neuropsychological Tests, Acquired immunodeficiency syndrome (AIDS), Antiretroviral Therapy, Highly Active, Internal medicine, Immunopathology, medicine, Humans, Prospective Studies, Cognitive impairment, Sida, Cognitive deficit, Chemotherapy, biology, business.industry, Cognitive disorder, biology.organism_classification, medicine.disease, Surgery, Treatment Outcome, Female, Neurology (clinical), Viral disease, medicine.symptom, business
Abstract

To assess the impact of highly active antiretroviral therapy (HAART) on AIDS-associated cognitive impairment, 22 patients with AIDS with (n = 11) and without (n = 11) cognitive deficit were evaluated clinically and by MRS every 3 months for 9 months. Nineteen patients were on HAART at study entry, 21 after 2 months. Cognitively impaired patients presented with a subcorticofrontal deficit and decreased N-acetyl-aspartate in frontal white matter. These clinical and metabolic abnormalities reversed partially on HAART, whereas they remained within normal limits in cognitively unimpaired patients.

Published
2001
Full Text
View/download PDF

36. Encephalitis after hepatitis B vaccination: Recurrent disseminated encephalitis or MS?

Author

E.A. Cabanis, C. Bougniot, Roland S. Liblau, M. T. Iba-Zizen, Ayman Tourbah, Olivier Gout, and Olivier Lyon-Caen

Subjects
Adult, Male, Multiple Sclerosis, business.industry, Multiple sclerosis, CNS demyelination, Encephalomyelitis, Brain, medicine.disease, Magnetic Resonance Imaging, Central nervous system disease, Vaccination, Acute disseminated encephalomyelitis, Immunology, medicine, Encephalitis, Humans, Female, Hepatitis B Vaccines, Neurology (clinical), Viral disease, Child, business
Abstract

Objective: To describe clinical and MRI features of patients with a disease suggestive of CNS inflammation after hepatitis B vaccination. Methods: Eight patients with confirmed CNS inflammation occurring less than 10 weeks after hepatitis B vaccination are described. They received follow-up clinically and on MRI for a mean period of 18 months. Results: Clinical and MRI findings were compatible with acute disseminated encephalomyelitis. However, clinical follow-up, repeated MRI, or both showed the persistence of inflammatory activity, which makes this encephalitis more suggestive of MS than of acute disseminated encephalomyelitis. Conclusion: The persistent inflammatory activity observed clinically and on MRI in these patients is comparable with that usually observed in MS. Epidemiologic studies are currently testing the hypothesis of a triggering role of hepatitis B vaccination in CNS demyelination.

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results